- Home
- DAWN vs WB Comparison
DAWN vs WB Comparison
Compare DAWN & WB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- WB
- Stock Information
- Founded
- DAWN 2018
- WB 2009
- Country
- DAWN United States
- WB China
- Employees
- DAWN N/A
- WB N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- WB Computer Software: Programming Data Processing
- Sector
- DAWN Health Care
- WB Technology
- Exchange
- DAWN Nasdaq
- WB Nasdaq
- Market Cap
- DAWN 1.3B
- WB N/A
- IPO Year
- DAWN 2021
- WB 2014
- Fundamental
- Price
- DAWN $12.54
- WB $9.54
- Analyst Decision
- DAWN Strong Buy
- WB Hold
- Analyst Count
- DAWN 7
- WB 7
- Target Price
- DAWN $36.17
- WB $10.23
- AVG Volume (30 Days)
- DAWN 1.0M
- WB 1.4M
- Earning Date
- DAWN 10-30-2024
- WB 11-19-2024
- Dividend Yield
- DAWN N/A
- WB N/A
- EPS Growth
- DAWN N/A
- WB N/A
- EPS
- DAWN N/A
- WB 1.44
- Revenue
- DAWN $101,953,000.00
- WB $1,761,517,000.00
- Revenue This Year
- DAWN N/A
- WB N/A
- Revenue Next Year
- DAWN $36.10
- WB $3.31
- P/E Ratio
- DAWN N/A
- WB $6.77
- Revenue Growth
- DAWN N/A
- WB 0.99
- 52 Week Low
- DAWN $11.94
- WB $7.03
- 52 Week High
- DAWN $18.07
- WB $12.40
- Technical
- Relative Strength Index (RSI)
- DAWN 38.87
- WB 46.33
- Support Level
- DAWN $12.43
- WB $9.56
- Resistance Level
- DAWN $13.03
- WB $10.06
- Average True Range (ATR)
- DAWN 0.46
- WB 0.33
- MACD
- DAWN 0.03
- WB -0.09
- Stochastic Oscillator
- DAWN 36.33
- WB 2.78
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.